You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020180019
Dec 202040013
Jan 20211604
Feb 20212605
Mar 20214807
Apr 20213004
May 202136010
Jun 2021008
Jul 2021009
Aug 2021007
Sep 2021005
Oct 202115023
Nov 202132020
Dec 20211603
Jan 20223000
Feb 202268011
Mar 202280026
Apr 20224802
May 20224403
Jun 20222402
Jul 20221404
Aug 20222606
Sep 20222206
Oct 20222606
Nov 20223003
Dec 202238019
Jan 20232403
Feb 20231801
Mar 20232006
Apr 20233805
May 20231403
Jun 20231400
Jul 20231603
Aug 20233002
Sep 2023600
Oct 20231602
Nov 20231802
Dec 20235001
Jan 20243201
Feb 20241801
Mar 20241800
Apr 20242206
May 20244202
Jun 20244003
Jul 20242204
Aug 20244002
Sep 20244601
Oct 20242607
Nov 20242203
Dec 202420011
Jan 20252407
Feb 2025208
Mar 2025006
Apr 2025009
May 2025005
Jun 2025004
Total15270333